Expression and its clinical significance of ERCC1 in stage Ⅱ colorectal carcinoma
10.7652/jdyxb201706022
- VernacularTitle:ERCC1在Ⅱ期结直肠癌中的表达及其临床意义
- Author:
Jing LIANG
1
;
an Wen WU
;
Lu BAI
;
juan Hui LIU
;
Ping Yi YANG
;
Qian WANG
;
ce Zhi ZHANG
;
Tao LI
Author Information
1. 西安交通大学医学部附属陕西省肿瘤医院放疗科
- Keywords:
colorectal carcinoma;
excision repair cross complementing gene 1 (ERCC1 );
adjuvant chemotherapy;
prognosis
- From:
Journal of Xi'an Jiaotong University(Medical Sciences)
2017;38(6):898-903,911
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression and clinical significance of excision repair cross complementing gene 1 (ERCC1 )in colorectal carcinoma of stage Ⅱ and its clinical significance.Methods We collected 56 cases of stage Ⅱ postoperative colorectal carcinoma tissue and detected ERCC1 expression with immunofluorescence technique.Statistical analysis was made with SPSS13.0 software.Results ERCC1 expression was obviously lower in stage II postoperative colorectal carcinoma tissue than in normal tissue (P =0.01).In cancer tissue,ERCC1 expression in patients with relapse or metastasis was significantly lower than in those without (P =0.002);ERCC1 expression in patients with T3 was significantly higher than those with T4 (P = 0.044).ERCC1 expression had a positive correlation with the overall survival (OS)and disease-free survival (DFS)(both P =0.000).In the group of high ERCC1 expression patients,five-year OS rate and DFS rate between patients who had received oxaliplatin-based adjuvant chemotherapy and those who did not have no significant difference (P =0.351;P =0.465).In the group of low ERCC1 expression patients,five-year OS rate and DFS rate of patients who received oxaliplatin-based adjuvant chemotherapy were significantly higher than those of patients who did not (P =0.015,P =0.02).ERCC1 (P =0.031 )and relapse or metastasis (P =0.009)were independent factors affecting OS;relapse or metastasis (P =0.000)was an independent factor affecting DFS.Conclusion ERCC1 is an independent factor affecting the OS of patients with stage Ⅱ colorectal carcinoma.Patients with low ERCC1 expression have poor prognosis,but they can benefit from oxaliplatin-based adjuvant chemotherapy.
